Meeting
2021 Gastrointestinal Cancers Symposium
Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases.
Presenter
Daryl Chia
Department of Surgery, University Surgical Cluster, National University Health System
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Rapid Oral Abstract Session
Session Title
Rapid Abstract Session: Esophageal and Gastric Cancer
Track
Esophageal and Gastric Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT01739894
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 165)
DOI
10.1200/JCO.2021.39.3_suppl.165
Abstract #
165
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Gastrointestinal Cancers Symposium
TST001 (a high affinity humanized anti-claudin18.2 monoclonal antibody) in combination with nivolumab plus capecitabine and oxaliplatin as first-line or with nivolumab as late-line treatment in locally advanced and metastatic gastric/gastroesophageal junction (G/GEJ) cancer: Design of cohorts from a phase I/IIa study (TST001-1002).
Speaker: Weijian Guo, MD,PhD
Videos & Slides
2021 ASCO Annual Meeting
Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial.
Speaker: Weijian Guo, MD,PhD
Speaker: Eliezer Mendel Van Allen, MD
Videos & Slides
2011 ASCO Annual Meeting
Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer.
Speaker: Eric Van Cutsem, MD, PhD